These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32985279)

  • 1. Resistance to peptidoglycan-degrading enzymes.
    Grishin AV; Karyagina AS; Vasina DV; Vasina IV; Gushchin VA; Lunin VG
    Crit Rev Microbiol; 2020 Nov; 46(6):703-726. PubMed ID: 32985279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.
    Oliveira H; São-José C; Azeredo J
    Viruses; 2018 May; 10(6):. PubMed ID: 29844287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications.
    Donovan DM
    Recent Pat Biotechnol; 2007; 1(2):113-22. PubMed ID: 19075835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage endolysins as a novel class of antibacterial agents.
    Borysowski J; Weber-Dabrowska B; Górski A
    Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections.
    Gondil VS; Harjai K; Chhibber S
    Int J Antimicrob Agents; 2020 Feb; 55(2):105844. PubMed ID: 31715257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phage lysins for intestinal microbiome modulation: current challenges and enabling techniques.
    Pottie I; Vázquez Fernández R; Van de Wiele T; Briers Y
    Gut Microbes; 2024; 16(1):2387144. PubMed ID: 39106212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzybiotics: Enzyme-Based Antibacterials as Therapeutics.
    Dams D; Briers Y
    Adv Exp Med Biol; 2019; 1148():233-253. PubMed ID: 31482502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endolysins as antimicrobials.
    Nelson DC; Schmelcher M; Rodriguez-Rubio L; Klumpp J; Pritchard DG; Dong S; Donovan DM
    Adv Virus Res; 2012; 83():299-365. PubMed ID: 22748813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriophages, phage endolysins and antimicrobial peptides - the possibilities for their common use to combat infections and in the design of new drugs.
    Mirski T; Lidia M; Nakonieczna A; Gryko R
    Ann Agric Environ Med; 2019 Jun; 26(2):203-209. PubMed ID: 31232046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.
    Vázquez R; García E; García P
    Front Immunol; 2018; 9():2252. PubMed ID: 30459750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria.
    Gerstmans H; Rodríguez-Rubio L; Lavigne R; Briers Y
    Biochem Soc Trans; 2016 Feb; 44(1):123-8. PubMed ID: 26862197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered phage enzymes against drug-resistant pathogens: a review on advances and applications.
    Hassannia M; Naderifar M; Salamy S; Akbarizadeh MR; Mohebi S; Moghadam MT
    Bioprocess Biosyst Eng; 2024 Mar; 47(3):301-312. PubMed ID: 37962644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria.
    Briers Y; Lavigne R
    Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysis of cells of diverse bacteria by l,d-peptidases of Escherichia coli bacteriophages RB43, RB49 and T5.
    Shadrin VS; Machulin AV; Dorofeeva LV; Chernyshov SV; Mikoulinskaia GV
    J Appl Microbiol; 2021 Jun; 130(6):1902-1912. PubMed ID: 33107183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phages amid antimicrobial resistance.
    Mohan Raj JR; Karunasagar I
    Crit Rev Microbiol; 2019; 45(5-6):701-711. PubMed ID: 31775552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Advantages and Challenges of Using Endolysins in a Clinical Setting.
    Murray E; Draper LA; Ross RP; Hill C
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33920965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biocatalytic Nanocomposites for Combating Bacterial Pathogens.
    Wu X; Kwon SJ; Kim J; Kane RS; Dordick JS
    Annu Rev Chem Biomol Eng; 2017 Jun; 8():87-113. PubMed ID: 28592177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid in situ procedure for determination of bacterial susceptibility or resistance to antibiotics that inhibit peptidoglycan biosynthesis.
    Santiso R; Tamayo M; Gosálvez J; Bou G; Fernández Mdel C; Fernández JL
    BMC Microbiol; 2011 Aug; 11():191. PubMed ID: 21867549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phage lytic enzymes--new hope in battle against bacterial infections].
    Niczyporuk JS; Bartoszcze M
    Przegl Epidemiol; 2007; 61(4):713-21. PubMed ID: 18572503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUF3380 Domain from a Salmonella Phage Endolysin Shows Potent N-Acetylmuramidase Activity.
    Rodríguez-Rubio L; Gerstmans H; Thorpe S; Mesnage S; Lavigne R; Briers Y
    Appl Environ Microbiol; 2016 Aug; 82(16):4975-81. PubMed ID: 27287318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.